United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - solution - 10 mg in 5 ml - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the concurrent use of nortriptyline hydrochloride or other tricyclic antidepressants with a monoamine oxidase (mao) inhibitor is contraindicated. hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. it is advisable to discontinue the mao inhibitor at least 2 weeks before treatment with nortriptyline hydrochloride is to be started. patients hypersensitive to nortriptyline hydrochloride should not be given the drug. cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - clotrimazole, quantity: 1 % w/w - cream - excipient ingredients: cetostearyl alcohol; cetomacrogol 1000; propylene glycol; purified water; methyl hydroxybenzoate; white soft paraffin; propyl hydroxybenzoate; liquid paraffin - a broad spectrum antifungal for the effective treatment of vaginal candidiasis (commonly referred to as thrush) and the relief of the associated symptoms,such as itching, burning and vaginal discharge.

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; propyl hydroxybenzoate; magnesium stearate; sodium lauryl sulfate; lactose; titanium dioxide; gelatin; pregelatinised maize starch; purified water; patent blue v; methyl hydroxybenzoate - treatment of vaginal thrush

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - dexchlorpheniramine maleate, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised starch; maize starch; lactose monohydrate - for the symptomatic treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated allergic skin,manifestations of urticaria and angioedema. it may relieve itching due to skin conditions such as allergic eczema, pruritus ani, pruritus vulvae, atopic,dermatitis, contact dermatitis, insect bites, dermographism and drug reactions, including serum sickness.

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - hydrocortisone acetate, quantity: 10 mg/g - cream - excipient ingredients: white soft paraffin; propylene glycol; cetomacrogol 1000; chlorocresol; dibasic sodium phosphate; monobasic sodium phosphate dihydrate; liquid paraffin; butylated hydroxytoluene - topical corticosteroid therapy for the temporary relief of symptoms of non-infected inflammatory conditions of the skin [e.g. minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to soap, detergent, cosmetics and jewellery), insect bites, itching anal and genital areas, and sunburn].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; purified talc; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.